参考文献/References:
[1].McDonagh TA,Metra M,Adamo M,et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2023,44(37):3627-3639.
[2].McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[3].Anker SD,Butler J,Filippatos G,et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med,2021,385(16):1451-1461.
[4].Solomon SD,McMurray JJV,Claggett B,et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med,2022,387(12):1089-1098.
[5].Solomon SD,de Boer RA,DeMets D,et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction:rationale and design of the DELIVER trial[J]. Eur J Heart Fail,2021,23(7):1217-1225.
[6].Solomon SD,Vaduganathan M,Claggett BL,et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction:DELIVER trial[J]. JACC Heart Fail,2022,10(3):184-197.
[7].Jhund PS,Kondo T,Butt JH,et al. Dapagliflozin across the range of ejection fraction in patients with heart failure:a patient-level,pooled meta-analysis of DAPA-HF and DELIVER[J]. Nat Med,2022,28(9):1956-1964.
[8].Lee DS,Straus SE,Farkouh ME,et al. Trial of an intervention to improve acute heart failure outcomes[J]. N Engl J Med,2023,388(13):22-32.
[9].Mebazaa A,Davison B,Chioncel O,et al. Safety,tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure(STRONG-HF):a multinational,open-label,randomised,trial[J]. Lancet,2022,400(10367):1938-1952.
[10].Heerspink HJL,Stefansson BV,Correa-Rotter R,et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med,2020,383(15):1436-1446.
[11].The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease[J]. N Engl J Med,2023,388(2):117-127.
[12].Nuffield Department of Population Health Renal Studies Group,SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes:collaborative meta-analysis of large placebo-controlled trials[J]. Lancet,2022,400(10365):1788-1801.
[13].Bakris GL,Agarwal R,Anker SD,et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med,2020,383(23):2219-2229.
[14].Pitt B,Filippatos G,Agarwal R,et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med,2021,385(24):2252-2263.
[15].Agarwal R,Filippatos G,Pitt B,et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease:the FIDELITY pooled analysis[J]. Eur Heart J,2022,43(6):474-484.
[16].Silverberg DS,Iaina A,Schwartz D,et al. Intravenous iron in heart failure:beyond targeting anemia[J]. Curr Heart Fail Rep,2011,8(1):14-21.
[17].Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia:a review of randomized controlled trials across different indications[J]. Arzneimittelforschung,2010,60(6a):386-398.
[18].Kalra PR,Cleland JGF,Petrie MC,et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK(IRONMAN):an investigator-initiated,prospective,randomised,open-label,blinded-endpoint trial[J]. Lancet,2022,400(10369):2199-2209.
[19].Ponikowski P,Kirwan BA,Anker SD,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure:a multicentre,double-blind,randomised,controlled trial[J]. Lancet,2020,396(10266):1895-1904.
[20].Graham FJ,Pellicori P,Kalra PR,et al. Intravenous iron in patients with heart failure and iron deficiency:an updated meta-analysis[J]. Eur J Heart Fail,2023,25(4):528-537.
[21].Salah HM,Savarese G,Rosano GMC,et al. Intravenous iron infusion in patients with heart failure:a systematic review and study-level meta-analysis[J]. ESC Heart Fail,2023,10(2):1473-1480.
[22].Vukadinovic D,Abdin A,Emrich I,et al. Efficacy and safety of intravenous iron repletion in patients with heart failure:a systematic review and meta-analysis[J]. Clin Res Cardiol,2023,112(7):954-966.
[23].Anker SD,Khan MS,Butler J,et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency:a Bayesian meta-analysis[J]. Eur J Heart Fail,2023,25(7):1080-1090.
[24].Macdougall IC,White C,Anker SD,et al. Intravenous iron in patients undergoing maintenance hemodialysis[J]. N Engl J Med,2019,380(5):447-458.
[25].Jhund PS,Petrie MC,Robertson M,et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy[J]. JACC Heart Fail,2021,9(7):518-527.